Increasing the efficiency of pharmacotherapy in comorbide patients with chronic brain ischemia on an outpatient basis

Authors:
T.L. Visil ¹ , E.G. Arefieva ²

¹ FSBEI in Kemerovo State Medical University of the Ministry of Health of Russia, Kemerovo, Russia;
² GBOUZ "Kuzbass Clinical Cardiological Dispensary named after Academician L.S. Barbarash ", Kemerovo, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2023, T. 123, No. 3

Summary:
Purpose of the study. Studying the effectiveness and safety of consistent therapy with Mexidol preparations (500 mg 1 time per day for 14 days in/c) and Mexidol Fort 250 (Mexol Fort 250 by 250 mg 3 times a day, 60 days) in patients with chronic brain ischemia ( Chem) on an outpatient basis.

Material and methods. The open comparative study included 56 patients aged 46–74 years (average - 60.5 ± 7.9 years). In all patients, the diagnosis of Khim was confirmed by clinical and neuroizialization methods. Patients of the 1st group (n = 28) received basic therapy and Mexidol, the 2nd group (n = 28)-only basic therapy.

Results. Against the background of therapy in patients of the 1st group, there was a statistically significant improvement in the state of cognitive functions, a decrease in the severity of the symptoms of depression and anxiety, and manifestations of asthenia. The treatment was characterized by good tolerance, the absence of undesirable phenomena and cases of drug interactions.

Conclusion. Consistent therapy with Mexidol and Mexidol Forte 250 ensures the relief of the main clinical manifestations of chemicals, is characterized by good tolerance and safety.

Keywords: chronic brain ischemia, arterial hypertension, ethylmethylhydroxypyrididine Succinate, Mexidol, Mexidol Forte 250.